Literature DB >> 30896761

Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply.

Roberto Ferrara1, Caroline Caramella2, Benjamin Besse1,3.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30896761     DOI： 10.1001/jamaoncol.2019.0138

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  2 in total

Review 1.  Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.

Authors:  Giuseppe Lo Russo; Francesco Facchinetti; Marcello Tiseo; Marina Chiara Garassino; Roberto Ferrara
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

2.  Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.

Authors:  David Gandara; Martin Reck; Denis Moro-Sibilot; Julien Mazieres; Shirish Gadgeel; Stefanie Morris; Andres Cardona; Diana Mendus; Marcus Ballinger; Achim Rittmeyer; Solange Peters
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.